Edition:
United Kingdom

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

16.97USD
9:00pm BST
Change (% chg)

$0.34 (+2.04%)
Prev Close
$16.63
Open
$16.85
Day's High
$17.11
Day's Low
$16.70
Volume
70,406
Avg. Vol
159,173
52-wk High
$27.00
52-wk Low
$10.30

Latest Key Developments (Source: Significant Developments)

D. E. Shaw & Co Reports 5.0% Passive Stake In Omeros Corp
Friday, 10 May 2019 

May 10 (Reuters) - D. E. Shaw & Co, L.P.: :D. E. SHAW & CO, L.P. REPORTS 5.0% PASSIVE STAKE IN OMEROS CORP AS OF APRIL 30 - SEC FILING.  Full Article

D. E. Shaw & Co Reports 5.1 Percent Passive Stake In Omeros Corp As Of Feb 26, 2019
Friday, 8 Mar 2019 

March 8 (Reuters) - Omeros Corp ::D. E. SHAW & CO REPORTS A PASSIVE STAKE OF 5.1 PERCENT IN OMEROS CORP AS OF FEB 26, 2019 - SEC FILING.  Full Article

Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Omeros Corp ::OMEROS FINALIZES WITH FDA CLINICAL PLAN FOR OMS721 APPROVAL IN IGA NEPHROPATHY.OMEROS CORP - ADDITIONAL POSITIVE DATA REPORTED FROM SECOND COHORT IN PHASE 2 TRIAL--.OMEROS CORP - ADDITIONAL POSITIVE DATA REPORTED FROM SECOND COHORT IN PHASE 2 TRIAL.OMEROS - OMS721 CONTINUES TO BE WELL TOLERATED AND NO SAFETY CONCERNS HAVE BEEN OBSERVED.OMEROS CORP - DURING FDA MEETING, IT WAS CONFIRMED THAT PHASE 3 TRIAL'S PRIMARY ENDPOINT OF ASSESSMENT OF PROTEINURIA WILL BE EXTENDED TO 36 WEEKS.  Full Article

Omeros Announces Proposed $210 Million Offering Of Convertible Senior Notes Due 2023
Thursday, 8 Nov 2018 

Omeros Corp ::OMEROS ANNOUNCES PROPOSED $210 MILLION OFFERING OF CONVERTIBLE SENIOR NOTES DUE 2023.OMEROS CORP - NOTES WILL MATURE ON NOVEMBER 15, 2023.OMEROS CORP-TO USE PORTION OF PROCEEDS OF OFFERING TO REPAY IN FULL AMOUNTS OUTSTANDING UNDER CO'S SECURED TERM LOAN AGREEMENT WITH CRG SERVICING LLC.  Full Article

Omeros Q3 Loss Per Share $0.81
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Omeros Corp ::OMEROS CORP REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.81.Q3 EARNINGS PER SHARE VIEW $-0.77 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $4.6 MILLION.Q3 REVENUE VIEW $3.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Omeros Corporation Announces Reinstatement Of Pass-Through Status For Omidria
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Omeros Corp ::OMEROS CORPORATION ANNOUNCES REINSTATEMENT OF PASS-THROUGH STATUS FOR OMIDRIA®.OMEROS CORP - CMS' SEPARATE PAYMENT FOR CATARACT SURGERY DRUG RESUMES TODAY.OMEROS CORP - CONTINUES TO PURSUE PERMANENT SEPARATE PAYMENT FOR OMIDRIA..OMEROS CORP - CONTINUES TO PURSUE PERMANENT SEPARATE PAYMENT FOR OMIDRIA.  Full Article

Omeros’ OMS721 Receives European Orphan Drug Designation
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Omeros Corp ::OMEROS’ OMS721 RECEIVES EUROPEAN ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR TREATMENT IN HEMATOPOIETIC STEM CELL TRANSPLANTATION.OMEROS CORP - DISCUSSIONS ONGOING WITH EUROPEAN REGULATORS FOR PATHWAY TO EXPEDITED APPROVAL.OMEROS CORP - POSITIVE OPINION EXPECTED TO BE ADOPTED BY EUROPEAN COMMISSION IN AUGUST.OMEROS CORP - INITIATED MANUFACTURING SCALE-UP PROCESS OF ITS MASP-3 ANTIBODIES IN PREPARATION FOR CLINICAL TRIALS.  Full Article

Omeros Corp Initiates Sales Of Omidria In Europe
Monday, 23 Jul 2018 

July 23 (Reuters) - Omeros Corp ::OMEROS CORPORATION INITIATES SALES OF OMIDRIA® IN EUROPE.OMEROS SAYS THESE INITIAL SALES OF OMIDRIA (PHENYLEPHRINE & KETOROLAC INTRAOCULAR SOLUTION) 1 PCT/0.3 PCT IN EUROPE SATISFY "SUNSET CLAUSE" PROVISION IN EU.  Full Article

FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721
Thursday, 26 Apr 2018 

April 26 (Reuters) - Omeros Corp ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO OMEROS’ MASP-2 INHIBITOR OMS721 FOR THE TREATMENT OF HIGH-RISK HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY.DISCUSSIONS ONGOING WITH FDA AND EUROPEAN REGULATORS FOR EXPEDITED APPROVAL OF OMS721.  Full Article

Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Omeros Corp ::OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY.OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY.OMEROS CORP - ‍INITIATES OMS721 PHASE 3 PROGRAM IN HCT-TMA​.OMEROS CORP - ‍ PATIENT ENROLLMENT FOR ITS PHASE 3 CLINICAL TRIAL EVALUATING OMS721 IN PATIENTS WITH IGA NEPHROPATHY IS EXPECTED TO BEGIN EARLY IN FEB.  Full Article